U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H20N2S
Molecular Weight 296.43
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHDILAZINE

SMILES

CN1CCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1

InChI

InChIKey=HTMIBDQKFHUPSX-UHFFFAOYSA-N
InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mmx/methdilazine-hydrochloride.html

Methdilazine is a phenothiazine compound with antihistaminic activity. Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. It is used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disorders.

CNS Activity

Originator

Approval Year

1960
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Mycobacterium spp. growth
2
Target ID: Mycobacterium spp. growth
Inhibitor
8297
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TACARYL

Approved Use

Used in the treatment of pruritus associated with pityriasis rosea.

Launch Date

3.78604814E11
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:6823
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6823
ChemicalBook
CB6501372
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6501372
PubMed

PubMed

TitleDatePubMed
Antimicrobial properties of methdilazine and its synergism with antibiotics and some chemotherapeutic agents.
1988 Jul
Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine.
1993 Jun
Altered membrane permeability as the basis of bactericidal action of methdilazine.
1998 Jul
Patents

Patents

US3435114
2

Sample Use Guides

In Vivo Use Guide
Usual adult and adolescent dose Oral, 8 mg every six to twelve hours as needed.
Route of Administration: Oral
In Vitro Use Guide
Methdilazine (Md) could inhibit various Mycobacterium spp. at 5-15 ug/ml concentrations in vitro as well as in vivo.
Name Type Language
METHDILAZINE
INN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
METHDILAZINE [VANDF]
Common Name English
10H-PHENOTHIAZINE, 10-((1-METHYL-3-PYRROLIDINYL)METHYL)-, MONOHYDROCHLORIDE
Common Name English
METHDILAZINE [MI]
Common Name English
methdilazine [INN]
Common Name English
TACARYL
Brand Name English
10-[(1-Methyl-3-pyrrolidinyl)methyl]phenothiazine
Systematic Name English
Methdilazine [WHO-DD]
Common Name English
METHDILAZINE [MART.]
Common Name English
METHDILAZINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29707
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
WHO-ATC R06AD04
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
WHO-VATC QR06AD04
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
Code System Code Type Description
SMS_ID
100000081430
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
DRUG BANK
DB00902
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
PUBCHEM
14677
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
INN
879
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
WIKIPEDIA
METHDILAZINE
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
RXCUI
29648
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY RxNorm
MESH
C044642
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
DRUG CENTRAL
1742
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
IUPHAR
7231
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
EVMPD
SUB08844MIG
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
MERCK INDEX
m7306
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY Merck Index
CHEBI
6823
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
ChEMBL
CHEMBL1200959
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
FDA UNII
4Q13LY9Z8X
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
NCI_THESAURUS
C66114
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
CAS
1982-37-2
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID6023282
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
ECHA (EC/EINECS)
217-841-6
Created by admin on Fri Dec 15 16:24:29 UTC 2023 , Edited by admin on Fri Dec 15 16:24:29 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of METHDILAZINE
SALT/SOLVATE (PARENT)
Structure of METHDILAZINE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966